Author: Prohost

The Value of Sangamo, Merck and AstraZeneca News

The Value of Sangamo, Merck and AstraZeneca News

GENE EDITING Sangamo Biosciences: Is it a Comeback? Genome editing allows the creation of therapeutics that can modify the genome in a living cell, providing unprecedented reach that would help the creation of treatments for genetic diseases. The dream about emerging solutions through genome editing techniques, which could correct genetic mutations causing diseases seems to be turning into reality. Among the innovative firms in this …
Who Is the New FDA Commissioner? What Happened to Roche’s Immunotherapy Drug?

Who Is the New FDA Commissioner? What Happened to Roche’s Immunotherapy Drug?

AT A GLANCE IMPORTANT NEWS A New FDA Commissioner The U.S. Senate Voted in Favor of Scott Gottlieb as the FDA Chief – Dr. Gottlieb, a medical doctor graduated from Mount Sinai – He held a high ranking position in the FDA during George W. Bush’s Presidency – Senators who voted for based their choice on Mr. Gottlieb’s knowledge of the FDA and of the …
Array Biopharma: When Clinical Trial Results Talk

Array Biopharma: When Clinical Trial Results Talk

Positive results were announced from Array’s (ARRY) Part 2 of the Phase 3 COLUMBUS study evaluating the firm’s MEK inhibitor drug binimetinib, and its BRAF inhibitor drug encorafenibin in patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The part 2 of the Phase 3, which intended to compare progression free survival (PFS) in patients treated with binimetinib plus encorafenib (COMBO300) to patients treated with encorafenib …
KITE Pharma: The Risk Versus the Reward

KITE Pharma: The Risk Versus the Reward

Indeed, Saving One Life is Important. Yet, Important Too is Saving Many Lives The Risk Vs. The Reward We keep repeating that the CAR-T treatment is created to stay, not because somebody loves the firms developing the CAR-T immunotherapy, but because this novel approach to cancer is saving the lives of the condemned. In addition, many reasons exist that make oncologists and regulators believe that …
Why Epizyme’s Upcoming Presentation Is More Than Exciting

Why Epizyme’s Upcoming Presentation Is More Than Exciting

EPIZYME Many oncologists, we believe, must be impatient to learn about the outcome of a first-in-class cancer drug based on epigenetics in upcoming oncology conventions. The drug tazemetostat was created and is being developed by Epizyme. Epizyme (EPZM) is a clinical-stage biotech company having proprietary platform, which  enabled it to identify and develop small molecule inhibitors of chromatin modifying proteins (CMPs), such as tazemetostat. CMPs, …
Novartis Agreements with Celyad and Bluebird Bio Say a Lot

Novartis Agreements with Celyad and Bluebird Bio Say a Lot

Novartis signed two different separate licensing agreements with two development-stage firms, Bluebird (BLUE) and Celyad (CYAD). The signing of the agreements, enabled Novartis to license the two firm’s proprietary technologies, both related to improving Novartis’ genetically engineered immunooncology CAR- T cells. CELYAD The Celyad/Novartis Agreement Celyad announced a non-exclusive license agreement with Novartis for its US patents issued for the production of allogeneic CAR-T cells. …
What Makes Merck and Array Shareholders Edgy

What Makes Merck and Array Shareholders Edgy

MERCK Merck (MRK) has beaten analysts’ expectations generating $9.4 billion for revenues in the first quarter of 2017. Its GAAP EPS was $0.56 for the first quarter of 2017 and the Non-GAAP EPS $0.88 for the first quarter of 2017. The outperformance occurred in spite of the declining sales of some aging drugs, which is a normal recurrent phenomenon especially with the increase in break-through …
Amgen: A Revolutionary Migraine Product Might Become the First to Reach the Clinic

Amgen: A Revolutionary Migraine Product Might Become the First to Reach the Clinic

MIGRAINE Migraine might have a new potent preventive treatment on the market in the near future. The new breakthrough approach towards migraine treatment aims at targeting and inhibiting calcitonin gene–related peptide (CGPR). Four drug developing firms have ongoing clinical trials with drugs targeting CGPR. These are Amgen/Novartis product erenumab (AMG334); Alder Pharmaceuticals’’ product ALD403 and Teva Pharmaceuticals’ product TEV-48125. Each of the monoclonal antibodies has …
ImmunoGen: What About Now?

ImmunoGen: What About Now?

ImmunoGen is one of two firms Prohost selected for investment on February 2011 based on the promises of its novel antibody-drug conjugate (ADC). An ADC drug is an antibody that carries highly potent cancer-killing agent attached to the antibody by a linker. The linker is designed to release an exceptionally toxic agent only as the ADC reaches the cancer cells in order not to harm …
Prohost Letter #408

Prohost Letter #408

Prohost Letter #408 AT A GLANCE - Continued from the Previous Prohost Letter #408 In the Past issue #407, we picked the following firms: NEUROCRINE BIOSCIENCES (NBIX) Treating Tardive Dyskinesia CYTOMX Improving On Cancer Immunotherapy CELYAD SA (CYAD) Bringing Solutions To Immunotherapy Problems Please Read the articles written about these firms in the Issue #407 In This Issue We Add  NEW LINK GENETICS...
Prohost Letter #407

Prohost Letter #407

Prohost Letter #407 AT A GLANCE - Firms Added to Prohost Portfolio PROHOST IS PICKING NEUROCRINE BIOSCIENCES   On March 27, a few days before the FDA approves Neurocrine’s (NBIX) drug Ingrezza, (valbenazine) capsules for adults with tardive dyskinesia (TD), we posted an article titled “Time for Transformation and Achievements”. In the article, we stated that Neurocrine Sciences Ingrezza will highlight Neurocrine Biosciences and its …
The Market Reaction Towards the FDA Complete Response Letter Offers a Unique Investment Opportunity In Incyte

The Market Reaction Towards the FDA Complete Response Letter Offers a Unique Investment Opportunity In Incyte

Eli Lilly (LLY) and Incyte (INCY) announced that the FDA has issued a complete response letter for the New Drug Application (NDA) of baricitinib for moderate-to-severe rheumatoid arthritis (RA). The FDA letter indicated that additional clinical data are required to determine the most appropriate doses. The FDA also stated that additional data are necessary for further characterization of safety concerns across treatment arms. The timing …
Neurocrine Biosciences: The Meaning of Ingrezza’s Approval for Tardive Dyskinesia (TD)

Neurocrine Biosciences: The Meaning of Ingrezza’s Approval for Tardive Dyskinesia (TD)

On March 27, we wrote about how positive results of Neurocrine Biosciences (NBIX) drug Ingrezza on Tardive Dyskinesia (TD) will highlight Neurocrine Biosciences and its Scientists. We wrote: The results published online by The American Journal of Psychiatry demonstrate that Phase 3 trial with Ingrezza conducted on patients with tardive dyskinesia showed significant and meaningful reduction in symptoms. We elaborated on the trial that provided …
CAR-T Immunotherapy Improvement. A Novel Approach and the Firm Behind It

CAR-T Immunotherapy Improvement. A Novel Approach and the Firm Behind It

CANCER IMMUNOTHERAPY 2 Nonstop Improvements and Nonstop Discoveries In CAR-T Immunotherapy As we said in the article about checkpoint inhibition as cancer immunotherapy, the approaches that aim at enabling the immune system to fight cancer cells were created to stay and improve and become the gold standard for cancer treatment. Chimeric antigen receptor T cell (CAR-T) therapeutics are speeding their way towards approval in 2017. …
The FDA Approves Gilead’s HCV Drugs Harvoni and Sovaldi for Adolescents

The FDA Approves Gilead’s HCV Drugs Harvoni and Sovaldi for Adolescents

The FDA Approves Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepatitis C Infection First HCV Direct-Acting Antivirals Approved for Adolescents Gilead Sciences (GILD) announced that the FDA has approved its supplemental application for its HCV drugs HARVONI® (ledipasvir 90 mg/sofosbuvir 400 mg) for pediatric patients with genotype 1, 4, 5 or 6 chronic HCV infection and its HCV drug SOVALDI® …
Advancements in Cancer Immunotherapy. See Also: A Small Firm with Promising News

Advancements in Cancer Immunotherapy. See Also: A Small Firm with Promising News

CANCER IMMUNOTHERAPY Nonstop Improvements and Nonstop Discoveries Checkpoint inhibitors and CAR-T immunotherapy are created to stay and succeed and change the way cancer has been treated for decades. The reason is that the successful results from some early attempts to enable the immune system to attack and fight cancers through these new immunotherapy approaches were unmatched in the history of cancer treatments. These successes, though, …
Agenus Reform and Downsizing. Innoviva’s Voting Dilemma

Agenus Reform and Downsizing. Innoviva’s Voting Dilemma

Agenus (AGEN) is reorganizing its business and operations. The reasons the firm cited comprise sharpening of its focus on clinical development of its two checkpoint inhibitor antibodies and vaccine program. Among others are: - Closing its Basel site and consolidate key functions to its Cambridge, UK and Lexington, MA facilities, - Phasing out approximately 50 positions across the organization. Robert Stein, M.D., Ph.D., President of …
Neurocrine BioSciences (NBIX): Time for Transformation and Achievements

Neurocrine BioSciences (NBIX): Time for Transformation and Achievements

Positive Results of INGREZZA on Tardive Dyskinesia Highlights Neurocrine Biosciences Sciences and Scientists     The results published online by The American Journal of Psychiatry demonstrate that Phase 3 trial with Neurocrine Biosciences (NBIX) drug Ingrezza conducted on patients with tardive dyskinesia showed significant and meaningful reduction in symptoms. The positive results came out of the Kinect 3 — a Phase 3, randomized, double-blind, placebo-controlled, parallel-group, …
CytomX Therapeutics: A Noteworthy Expansion of Collaborative Agreement with BMY

CytomX Therapeutics: A Noteworthy Expansion of Collaborative Agreement with BMY

Everybody knows Bristol-Myers Squibb (BMY), but just a few may know anything about CytomX Therapeutics (CTMX), or about its Probody Program. CytomX is a small, develop-ment-stage firm that created platform known as the Probody Program, which leads to the creation of first in class Probody therapeutics. These therapeutics are meant to overcome safety and efficacy problems encountered by the antibodies that are currently used in …
Amgen’s Underrated Great News. Array Pharma’s Smart Move

Amgen’s Underrated Great News. Array Pharma’s Smart Move

AMGEN Amgen’s (AMGN) cholesterol lowering drug Repatha is the only drug that has demonstrated protection against heart attack and stroke in high risk patients. Prior to the FOURIER trial, which confirmed the effect of Repatha in lowering cardiovascular events, including heart attack and stroke, other clinical trial data led to the FDA approval of Repatha limited to the following indications: 1) adjunct to diet and …